Which statement about GLP-1 receptor agonists is NOT supported by the material?

Which statement about GLP-1 receptor agonists is NOT supported by the material?

• A. They can be used for type 2 diabetes and weight loss.
• B. Tirzepatide is a GLP-1 receptor agonist.
• C. Semaglutide is a GLP-1 receptor agonist.
• D. They have no adverse effects.

Answer: (D)

GLP-1 receptor agonists help lower blood glucose and often promote weight loss, making them useful in type 2 diabetes management and in weight management strategies. Tirzepatide belongs to this class because it activates the GLP-1 pathway (even though it also targets GIP). Semaglutide is a well-known GLP-1 receptor agonist. A key point about these drugs is that they can cause adverse effects, most commonly gastrointestinal symptoms like nausea, vomiting, and diarrhea, and there are potential risks such as pancreatitis or gallbladder issues in some patients. Because of these known adverse effects, the statement that they have no adverse effects is not supported.

GLP-1 receptor agonists help lower blood glucose and often promote weight loss, making them useful in type 2 diabetes management and in weight management strategies. Tirzepatide belongs to this class because it activates the GLP-1 pathway (even though it also targets GIP). Semaglutide is a well-known GLP-1 receptor agonist. A key point about these drugs is that they can cause adverse effects, most commonly gastrointestinal symptoms like nausea, vomiting, and diarrhea, and there are potential risks such as pancreatitis or gallbladder issues in some patients. Because of these known adverse effects, the statement that they have no adverse effects is not supported.